Acclarent

Product

Last mentioned: Feb 26, 2026

Timeline

  1. Q4 2025 Earnings

    Company reports results and provides 2026 guidance, signaling continued remediation efforts.

  2. Projected Restart

    Target window for the commercial re-launch of SurgiMend and PriMatrix products.

  3. New Leadership

    Mojdeh Poul assumes role as CEO to lead the company's quality and operational turnaround.

  4. Boston Recall

    Integra initiates voluntary recall of all products manufactured in Boston due to endotoxin concerns.

Stories mentioning Acclarent 1

earnings Neutral

Integra LifeSciences Faces Market Pressure as Turnaround Timeline Extends

Integra LifeSciences (IART) shares faced downward pressure following its Q4 2025 earnings call, as management detailed an extended timeline for its Boston facility restart and the ongoing costs of its Quality Excellence Program. While the company provided its first full-year 2026 guidance, investor caution remains high regarding the path to normalized growth and product re-launches.

2 sources